Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon hosted a Preclinical Development of Innovative Drugs Summit

Page View:

Followed by 3 Chinese New Year & 10th Anniversary Gala Dinners hosted in USA, Medicilon hosted the fourth anniversary gala dinner along with the pre-clinical development of innovative drugs summit on Feb 28, 2014 in Shanghai.

The summit was hosted in the morning of Feb 28th while the gala dinner was hosted in the evening.  During the summit, Dr. Ding Jian – Chinese Academy of Engineering, Shanghai Institute of Materia Medica, Chinese Academy Director – gave a speech on the topic about the global strategy and challenges of innovative drugs and opportunities.

Both the summit and dinner were incredible success.  It was great to have the opportunity to meet so many life science peers in the same room, enjoying themselves.

Medicilon is a Preclinical Research Outsourcing (CRO) company. With more than 10 years of experience on preclinical research services, we are dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to select the most valuable drug candidates for clinical development.
Medicilon's preclinical research services consist of three major parts: pharmacokinetics, disease models and drug safety evaluation. Our preclinical research services cover design, in vivo studies, sample analysis, data analysis, IACUC review, and the preparation of regulatory application materials.

Related Articles:

Preclinical and clinical stages of drug development

Medicilon pushes on preclinical development of drugs

Relevant newsRelevant news